Study of fulvestrant with ribociclib for advanced breast cancer after prior treatment
Part of Cancer clinical trials.
This trial tests a combination of two drugs (fulvestrant and ribociclib) against other standard treatments for people whose hormone-receptor-positive, HER2-negative breast cancer has returned at least one year after finishing a prior CDK4/6 inhibitor (like abemaciclib or ribociclib). It aims to find a better option for those with advanced disease that can't be cured.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older.
- Your breast cancer is hormone-receptor-positive and HER2-negative, and it has spread or come back in a way that cannot be cured.
- You took either abemaciclib or ribociclib for at least 1 year as part of your initial treatment.
- Your cancer came back at least 1 year after your last dose of that CDK4/6 inhibitor.
- You also took hormone therapy for at least 2 years (with or without the CDK4/6 inhibitor).
- You are in good enough health to be up and about (ECOG score 0 or 1) and have at least one tumor that can be measured on scans or a bone lesion.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether adding abemaciclib to fulvestrant can slow or shrink ER-positive, HER2-negative metastatic breast cancer. It is mainly for people whose cancer has progressed despite prior treatment with a CDK4/6 inhibitor and an aromatase inhibitor.
This trial tests a combination of three drugs (inavolisib, ribociclib, and fulvestrant) compared to a placebo plus two of the drugs (ribociclib and fulvestrant) for people with advanced hormone receptor-positive breast cancer who have not had prior treatment for advanced disease. The goal is to see if adding inavolisib improves outcomes.
This trial tests a new medicine called fulvestaciclib combined with hormone therapy and anti-HER2 treatment for advanced breast cancer that is hormone receptor-positive and HER2-positive. It is for patients who have not had prior treatment for advanced disease and may help control tumor growth.
This Phase 1/2 study tests how well a new treatment combination (VS-6766, abemaciclib, and fulvestrant) works for metastatic or hard-to-remove breast cancer that is hormone-driven (ER/PR positive) and HER2 negative. It is mainly designed to find the safest dose and then see whether it can control the cancer after it has progressed on certain prior medicines.
This Phase 2 study compares two combinations of hormone-blocking drugs plus an anti-cancer targeted pill to see which works better for hormone-receptor positive, HER2-negative metastatic breast cancer. It may help by finding a more effective treatment plan when the cancer has spread.
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
Hear when a new Breast Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.